ArticleJACC. Advances2024
Cardiometabolic Disease Staging and Major Adverse Cardiovascular Event Prediction in 2 Prospective Cohorts.
Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of pharmacy education and practice on prevention and management of noncommunicable diseases in ASEAN countries.Scientific reports · 2025Pooled it
- Weight Loss Improves Predicted 10-Year MACE and Type 2 Diabetes Risk, but Benefits Partially Rebound at 1 Year.Obesity (Silver Spring, Md.) · 2026Trial
- Integrating social and cardiometabolic risk factors in predicting cardiometabolic multimorbidity: a Bayesian model development and internal validation in Swedish middle-aged adults.Scientific reports · 2026Article
- Real-world cardiovascular safety profile of bexarotene for the treatment of mycosis fungoides.Clinical and experimental medicine · 2026Article
- Integrated Epidemiological and Extracellular Vesicle Profiling Identifies miR-126-3p, miR-21-5p, miR-92a-3p and SNAIL as Candidate Biomarkers of Endothelial Dysfunction and Cardio-Metabolic Risk.International journal of molecular sciences · 2026Article
- The association of SPISE with cardiometabolic multimorbidity and stroke in middle-aged and older adults: a nationwide prospective cohort study.Scientific reports · 2026Article
- Primary care engagement in hidradenitis suppurativa: Influence of disease severity, cardiometabolic risk, and access barriers.Dermatology online journal · 2026Article
- Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Current Appraisal and Gaps in Knowledge in Cardio-Kidney Metabolic Syndrome Definition.International journal of molecular sciences · 2026Review
- Risks of cardiometabolic diseases in women with history of adverse pregnancy outcomes.Journal of human hypertension · 2026Review
- The evaluation of facial features as markers of cardiometabolic health in women of post-reproductive age.Evolution, medicine, and public health · 2026Article
- Skeletal Muscle-Cardiac Muscle Aging: Shared Mechanisms and Multimodal Interventions.JACC. Advances · 2025Review
- Adding social determinants of health to the equation: Development of a cardiometabolic disease staging model using clinical and social determinants of health to predict type 2 diabetes.Diabetes, obesity & metabolism · 2025Article
- Multifaceted Role of Apolipoprotein C3 in Cardiovascular Disease Risk and Metabolic Disorder in Diabetes.International journal of molecular sciences · 2024Review
- Primary and residual cardiometabolic risk factors among young adults in a Russian city.Journal of health, population, and nutrition · 2024Article
- Cardiometabolic Risk: Shifting the Paradigm Toward Comprehensive Assessment.JACC. Advances · 2024Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
backgroundCardiometabolic risk prediction models that incorporate metabolic syndrome traits to predict cardiovascular outcomes may help identify high-risk populations early in the progression of cardiometabolic disease.
objectivesThe purpose of this study was to examine whether a modified cardiometabolic disease staging (CMDS) system, a validated diabetes prediction model, predicts major adverse cardiovascular events (MACE).
methodsWe developed a predictive model using data accessible in clinical practice [fasting glucose, blood pressure, body mass index, cholesterol, triglycerides, smoking status, diabetes status, hypertension medication use] from the REGARDS (REasons for Geographic And Racial Differences in Stroke) study to predict MACE [cardiovascular death, nonfatal myocardial infarction, and/or nonfatal stroke]. Predictive performance was assessed using receiver operating characteristic curves, mean squared errors, misclassification, and area under the curve (AUC) statistics.
resultsAmong 20,234 REGARDS participants with no history of stroke or myocardial infarction (mean age 64 ± 9.3 years, 58% female, 41% non-Hispanic Black, and 18% diabetes), 2,695 developed incident MACE (13.3%) during a median 10-year follow-up. The CMDS development model in REGARDS for MACE had an AUC of 0.721. Our CMDS model performed similarly to both the ACC/AHA 10-year risk estimate (AUC 0.721 vs 0.716) and the Framingham risk score (AUC 0.673).
conclusionsThe CMDS predicted the onset of MACE with good predictive ability and performed similarly or better than 2 commonly known cardiovascular disease prediction risk tools. These data underscore the importance of insulin resistance as a cardiovascular disease risk factor and that CMDS can be used to identify individuals at high risk for progression to cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.